Lyell Immunopharma has entered into a definitive agreement for the acquisition of ImmPACT Bio USA, a move that is expected to prioritise its pipeline to focus on chimeric antigen receptor (CAR) T-cell therapies.
Bristol Myers Squibb (BMS) has entered into worldwide capacity reservation and supply agreement with Integrated Development and Manufacturing Organisation (IDMO) Cellares to bolster the manufacturing of chimeric antigen receptor (CAR) T cell therapies.
AGC Biologics has concluded expansion of its manufacturing area at its Cell & Gene Center of Excellence production site in Milan, Italy.
eXmoor pharma has received an investment of around $35m in its Series A round to support the expansion of its cell and gene therapy production capability.
Biotechnology company CAMP4 Therapeutics has closed a $100m Series B round to progress its lead regRNA programmes and speed up the expansion of its regRNA Actuating Platform.
Castle Creek Biosciences, a US-based late-stage cell and gene therapy company, has raised $112.8m to progress new gene therapies and expand pipeline.
ViGeneron, a Germany-based gene therapy company, has entered a target-specific strategic collaboration and option agreement with Regeneron Pharmaceuticals.
Charles River Laboratories International has agreed to buy Vigene Biosciences, a contract development and manufacturing organisation (CDMO) focused on gene therapies, for about $292.5m in cash.
Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment.
Eli Lilly and Company (Lilly) has joined hands with local health systems in the US state of Indiana to provide antibody therapies through dedicated infusion centre locations that will offer treatments for patients with COVID-19.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.